GERON CORP (GERN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 120.13M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 519.01M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $120.13M | (m) | (m) | $519.01M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $119.83M | (m) | (m) | $534.12M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $119.55M | (m) | (m) | $570.54M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $119.26M | (m) | (m) | $567.38M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $118.99M | (m) | (m) | $555.20M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $118.73M | (m) | (m) | $562.45M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $118.48M | (m) | $406.57M | $593.78M | (m) |
| 2024-09-30 | (m) | (m) | $71.56M | $12.28M | (m) | $339.77M | $444.95M | (m) |
| 2024-06-30 | (m) | (m) | $46.92M | $36.52M | (m) | $362.73M | $449.40M | (m) |
| 2024-03-31 | (m) | (m) | $71.53M | $11.22M | (m) | $443.05M | $482.07M | (m) |
| 2023-12-31 | (m) | (m) | $46.89M | $35.05M | (m) | $333.70M | $394.08M | (m) |
| 2023-09-30 | (m) | (m) | $22.06M | $29.84M | (m) | $313.53M | $413.02M | (m) |
| 2023-06-30 | (m) | (m) | $10.84M | $40.80M | (m) | $371.38M | $415.30M | (m) |
| 2023-03-31 | (m) | (m) | $0.00 | $51.40M | (m) | $380.74M | $424.88M | (m) |
| 2022-12-31 | (m) | (m) | $20.95M | $30.21M | (m) | $172.75M | $190.57M | (m) |
| 2022-09-30 | (m) | (m) | $12.96M | $37.80M | (m) | $194.79M | $232.61M | (m) |
| 2022-06-30 | (m) | (m) | $5.16M | $45.26M | (m) | $219.29M | $238.16M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $50.18M | (m) | $166.67M | $198.42M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $49.83M | (m) | $183.72M | $226.03M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $34.67M | (m) | $176.12M | $229.10M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $34.42M | (m) | $198.24M | $252.18M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $24.22M | (m) | $211.03M | $258.61M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $24.04M | (m) | $196.28M | $270.73M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $23.89M | (m) | $227.62M | $285.79M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |